News — Freemasons Centre for Male Health & Wellbeing

prostate cancer

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A.
Nat Cell Biol. 2021 Sep;23(9):1023-1034. doi: 10.1038/s41556-021-00743-5. Epub 2021 Sep 6.PMID: 34489572
Contact: Luke Selth

World first study to catalog all lipid species in prostate cancer - informing future treatment strategies

World first study to catalog all lipid species in prostate cancer - informing future treatment strategies

Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, Spotbeen X, Bagadi M, Waltregny D, Moldovan M, Dehairs J, Vanderhoydonc F, Bloch K, Das R, Stahl J, Kench JG, Gevaert T, Derua R, Waelkens E, Nassar ZD, Selth LA, Trim PJ, Snel MF, Lynn DJ, Tilley WD, Horvath LG, Centenera MM, Swinnen JV.
Cancer Res. 2021 Aug 6:canres.3863.2020. doi: 10.1158/0008-5472.CAN-20-3863. PMID: 34362796
Contact: Lisa Butler

Optimisation of on-line exercise guide for men with metastatic prostate cancer

Optimisation of on-line exercise guide for men with metastatic prostate cancer

Usability, acceptability, and safety analysis of a computer-tailored web-based exercise intervention (ExerciseGuide) for individuals with metastatic prostate cancer: Multi-methods laboratory-based study..
Evans HE, Forbes CC, Galvão DA, Vandelanotte C, Newton RU, Wittert G, Chambers S, Vincent AD, Kichenadasse G, Girard D, Brook N, Short CE. JMIR Cancer. 2021 Jul 28;7(3):e28370. doi: 10.2196/28370. PMID: 34318759;
Contact: Holly Evans

Technique for rapid screening of potential drug agents for prostate cancer

Technique for rapid screening of potential drug agents for prostate cancer

High-throughput imaging assay for drug screening of 3D prostate cancer organoids. Choo N, Ramm S, Luu J, Winter JM, Selth LA, Dwyer AR, Frydenberg M, Grummet J, Sandhu S, Hickey TE, Tilley WD, Taylor RA, Risbridger GP, Lawrence MG, Simpson KJ.SLAS Discov. 2021 Jun 11:24725552211020668. doi: 10.1177/24725552211020668.
Contact: Wayne Tilley

Study extends evidence on circulating fats and clinical outcomes for men with prostate cancer

Study extends evidence on circulating fats and clinical outcomes for men with prostate cancer

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, Mahon KL, Mak B, Sutherland PD, Shepherd A, Mellett N, Docanto M, Giles C, Centenera MM, Butler LM, Meikle PJ, Horvath LG.
Prostate Cancer Prostatic Dis. 2021 Mar 21. doi: 10.1038/s41391-021-00338-z.
Contact: Lisa Butler

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5: Inching closer to a new therapeutic strategy for prostate cancer

ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer
Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zininos I, Dehairs J, Burvenich IJG, Zadra G, Chetta P, Bango C, Evergren E, Ryan NK, Gillis JL, Mah CY, Tieu T, Hanson AR, Carelli R, Bloch K, Panagopoulos V, Waelkens E, Derua R, Williams ED, Evdokioou A, Cifuentes-Rius A, Voelcker NH, Mills IG, Tilley WD, Scott AM, Loda M, Selth LA, Swinnen JV, Butler LM. Cancer Res. 2021 Feb 5:canres.2511.2020. doi: 10.1158/0008-5472.CAN-20-2511.
Contact: Maggie Centenera

Cancer Council Women in Leadership Award: Professor Lisa Butler

Professor Lisa Butler, Member of FCMHW SA Management Group and Head of Prostate Cancer Laboratory (The University of Adelaide & South Australian Health & Medical Research Institute), has been awarded $50,000 as part of Cancer Council’s Women in Leadership Awards.

The Women in Leadership Awards, established in 2020, recognises women who are leading the way in South Australian cancer research. Cancer Council SA Chief Executive Lincoln Size said that the four women awarded are true leaders in their field and was proud to be able to recognise their efforts through the award.

Professor Butler’s award will support fresh prostate cancer tissue collection and biobanking from consenting patients who are undergoing surgery for prostate cancer in Adelaide.

“This collection is essential for my research program, which is unique in its use of fresh and archival prostate specimens to maximise clinical translation of our laboratory research findings,” she said.

180703_AUNI_LISA_133.jpg

Major support from the Hospital Research Foundation for prostate cancer research

The Centre congratulates two of its post-doctoral research fellows, Dr Zeyad Nassar and Dr Maggie Centenera, from the Prostate Cancer Research Group at the South Australian Health and Medical Research Institute on both being awarded research grants ($149,956 and $149,662 respectively) from the Hospital Research Foundation in its recently announced round.

Dr Nassar’s research will be targeting fatty acid oxidation for treatment of high risk localised prostate cancer, while Dr Centenera’s research will explore a patient-derived discovery platform for companion biomarker development in prostate cancer.

We acknowledge and thank the South Australian community for their generous donations to the Hospital Research Foundation to enable this research.

Prostate cancer and exercise: Protocol for pilot study currently recruiting men

Prostate cancer and exercise: Protocol for pilot study currently recruiting men

Evaluating a web- and telephone-based personalised exercise intervention for individuals living with metastatic prostate cancer (ExerciseGuide): protocol for a pilot randomised controlled trial
Evans HEL, Forbes CC, Galvão DA, Vandelanotte C, Newton RU, Wittert G, Chambers S, Vincent AD, Kichenadasse G, Brook N, Girard D, Short CE.
Pilot Feasibility Stud. 2021 Jan 11;7(1):21. doi: 10.1186/s40814-020-00763-2.
Contact: Camille Short

miR-194: a potential therapeutic target to prevent drug resistant prostate cancer

miR-194: a potential therapeutic target to prevent drug resistant prostate cancer

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
Fernandes RC, Toubia J, Townley S, Hanson AR, Dredge BK, Pillman KA, Bert AG, Winter JM, Iggo R, Das R, Obinata D; MURAL investigators, Sandhu S, Risbridger GP, Taylor RA, Lawrence MG, Butler LM, Zoubeidi A, Gregory PA, Tilley WD, Hickey TE, Goodall GJ, Selth LA. Cell Rep. 2021 Jan 5;34(1):108585. doi: 10.1016/j.celrep.2020.108585.
Contact: Luke Selth